Dual Targeting: Faricimab – A Bispecific Antibody Approach

Time: 11:30 am
day: Day One


  • Faricimab is the first innovation since over 15 years of antiVEGF monotherapy that adds a new MoA (Ang2) to the management of patients suffering from retinal vascular diseases such as nAMD and DME
  • Pre-clinical data provides a strong rationale that targeting Ang2 increases vascular stability and reduces inflammation
  • Phase 3 clinical data in both nAMD and DME shows that dual VEGF/Ang2-inhibition driven vascular stability with Faricimab translates into increased durability